Majority of Women Prefer Non-Invasive Testing for Trisomy 21
FRIDAY, Dec. 15, 2017 -- The majority of both high-risk and intermediate-risk women prefer a non-invasive cell-free prenatal DNA screening (NIPT) as a secondary screening test for trisomy 21, according to a study published online Nov. 10 in BJOG: An International Journal of Obstetrics and Gynaecology.
Yvonne Kwun Yue Cheng, M.B.Ch.B., from The Chinese University of Hong Kong, and colleagues examined preference for follow-up testing in women who were screened as high or intermediate risk in first- or second-trimester Down syndrome screening. Testing options included either an invasive test plus chromosomal microarray to obtain more detailed fetal genetic information or a NIPT to detect trisomies 13, 18, and 21 to avoid procedure-related miscarriage; the participants could also decline further testing.
The researchers found that of the 347 high-risk women, nearly all (99.1 percent) opted for follow-up testing, of whom 62.2 percent (216 women) chose NIPT. Of the 614 participants with intermediate risk, 82.6 percent (507 women) chose NIPT. Twenty-one percent of 34 women with nuchal translucency ≥3.5 mm opted for NIPT.
"In a setting where reporting times are similar and there is no cost difference between options, approximately 60 percent of high-risk women would opt for NIPT offering simple but limited aneuploidy assessment over a diagnostic procedure with comprehensive and more detailed assessment," the authors write.
One author disclosed a royalty-producing patent related to non-invasive prenatal diagnostics.
© 2020 HealthDay. All rights reserved.
Posted: December 2017
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.